USNA — USANA Health Sciences, Inc. stock price, charts and financials
QT35USANA Health Sciences, Inc.USANA Health Sciences, Inc. (NYSE: USNA) is a Consumer Defensive company in the Household & Personal Products industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | 0.47 | Insider Own | 47.51% | Shs Outstand | 18.46M | Perf Week | -30.03% |
| Market Cap | 285.62M | Forward P/E | 8.74 | EPS next Y | 1.77 | Insider Trans | -0.49% | Shs Float | 9.87M | Perf Month | -29.78% |
| Enterprise Value | 136.87M | PEG | 0.08 | EPS next Q | - | Inst Own | - | Short Float | 7.63% | Perf Quarter | -20.50% |
| Income | -22.14M | P/S | 0.31 | EPS this Y | 61.70% | Inst Trans | - | Short Ratio | 6.77 | Perf Half Y | -25.66% |
| Sales | 913.09M | P/B | 0.53 | EPS next Y | 132.89% | ROA | -3.00% | Short Interest | 753.03K | Perf YTD | -21.19% |
| Book/sh | - | P/C | 17.20 | EPS next 5Y | 132.89% | ROE | -4.15% | 52W High | 30.07 -52.13% | Perf Year | -46.73% |
| Cash/sh | - | P/FCF | 96.46 | EPS past 3/5Y | -45.54% -37.03% | ROIC | -22.41% | 52W Low | 13.35 7.80% | Perf 3Y | -76.09% |
| Dividend Est. | - | EV/EBITDA | 4.20 | Sales past 3/5Y | -2.53% -4.01% | Gross Margin | 77.45% | Volatility | 7.18% 4.94% | Perf 5Y | -83.76% |
| Dividend TTM | - | EV/Sales | 0.15 | EPS Y/Y TTM | -78.54% | Oper. Margin | 1.35% | ATR (14) | 1.39 | Perf 10Y | -77.44% |
| Dividend Ex-Date | - | Quick Ratio | 1.69 | Sales Y/Y TTM | 8.30% | Profit Margin | -2.43% | RSI (14) | 29.63 | Recom | 2.88 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.51 | EPS Q/Q | -16.44% | SMA20 | -26.79% | Beta | 0.66 | Target Price | 35.00 |
| Payout | 0.00% | Debt/Eq | 0.03 | Sales Q/Q | 0.00% | SMA50 | -23.83% | Rel Volume | 1.82 | Prev Close | 15.47 |
| Employees | 1,570 | LT Debt/Eq | 0.02 | Earnings | Oct 28 | SMA200 | -21.60% | Avg Volume | 129.54K | Price | 14.39 |
| IPO Date | Apr 04, 1994 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 38.64% 3.74% | Net Debt/EBITDA | -4.56 | Volume | 236,198 | Change | -6.95% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-23-24 | Reiterated | DA Davidson | Neutral | $38 → $35 |
| Jul-25-24 | Reiterated | DA Davidson | Neutral | $46 → $38 |
| May-07-24 | Reiterated | DA Davidson | Neutral | $46 |
| Jul-07-22 | Downgrade | Jefferies | Hold → Underperform | |
| Apr-27-22 | Reiterated | DA Davidson | Neutral | |
| Jul-03-19 | Downgrade | Sidoti & Co. | Buy → Neutral | |
| Apr-23-18 | Downgrade | Pivotal Research | Buy → Hold | |
| Jan-24-18 | Downgrade | Sidoti & Co. | Buy → Neutral | |
| May-03-17 | Upgrade | Pivotal Research | Hold → Buy | |
| May-01-17 | Downgrade | Pivotal Research | Buy → Hold |
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration. It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online. The company was founded in 1992 and is headquartered in Salt Lake City, Utah.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 1/3/2026 | FY 2024 12/28/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 913 | 925 | 855 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 205 | 201 | 176 | — | — | — | — | — | — | |
| Gross Profit | 708 | 724 | 679 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 334 | 337 | 601 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 12 | — | — | — | — | — | — | |
| Other Operating Expense | 362 | 337 | -1 | — | — | — | — | — | — | |
| Operating Income | 12 | 51 | 66 | — | — | — | — | — | — | |
| Interest Expense | 0 | 1 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -9 | -8 | 10 | — | — | — | — | — | — | |
| Net Income Before Taxes | 2 | 42 | 76 | — | — | — | — | — | — | |
| Income Taxes | 32 | 30 | 34 | — | — | — | — | — | — | |
| Consolidated Net Income | -22 | 11 | 42 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -30 | 11 | 42 | — | — | — | — | — | — | |
| Net Income | -22 | 11 | 42 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.21 | 0.58 | 2.20 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.21 | 0.58 | 2.20 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.21 | 0.58 | 2.19 | — | — | — | — | — | — | |
| EBITDA | 32 | 82 | 99 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 33.52 | 16.30 | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.28 | 0.40 | 0.79 | — | — | — | — | — | — | |
| Gross Margin | 77.55 | 78.27 | 79.42 | — | — | — | — | — | — | |
| Operating Margin | 1.31 | 5.51 | 7.72 | — | — | — | — | — | — | |
| Net Margin | -2.41 | 1.19 | 4.91 | — | — | — | — | — | — | |
| Shares Outstanding | 18 | 19 | 19 | — | — | — | — | — | — | |
| Market Capitalization | 259 | 369 | 678 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Benedict Peter | CHIEF INFORMATION OFFICER | Jul 25 '26 | Option Exercise | 0.00 | 598 | 0 | 598 | Jul 27 |
| Armstrong Kathryn Michelle | CHIEF SCIENTIFIC OFFICER | Jul 25 '26 | Option Exercise | 0.00 | 1,166 | 0 | 3,989 | Jul 27 |
| FULLER GILBERT A | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 1,632 | Jul 27 |
| Pelosi Peggie | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 6,996 | Jul 27 |
| Fleming John Turman | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 5,862 | Jul 27 |
| Ding Xia | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 8,882 | Jul 27 |
| WOOD TIMOTHY E | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 12,245 | Jul 27 |
| Winssinger Frederic J | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 9,733 | Jul 27 |
| Nixon J Scott | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 11,445 | Jul 27 |
| Neidig Brent | CHIEF COMMERCIAL OFFICER | Jun 16 '26 | Sale | 19.45 | 5,002 | 97,304 | 0 | Jun 18 |
| Neidig Brent | CHIEF COMMERCIAL OFFICER | Jun 15 '26 | Sale | 20.00 | 909 | 18,185 | 5,002 | Jun 16 |
| Neidig Brent | CHIEF COMMERCIAL OFFICER | Jun 12 '26 | Sale | 20.15 | 1,602 | 32,280 | 5,911 | Jun 16 |
| Jones Paul A. | CHIEF PEOPLE OFFICER | Jun 08 '26 | Sale | 18.50 | 5,561 | 102,879 | 0 | Jun 08 |
| Fleming John Turman | Director | Jun 01 '26 | Sale | 17.93 | 2,450 | 43,929 | 4,230 | Jun 01 |
| Jones Paul A. | CHIEF PEOPLE OFFICER | May 28 '26 | Sale | 18.95 | 6,813 | 129,106 | 5,561 | May 29 |